Previous 10 | Next 10 |
Rivian Automotive ( RIVN ) represented one of Wall Street's notable gainers in Thursday's midday trading. Shares of the electric vehicle maker rose on word of a key partnership. Snap ( SNAP ) was another intraday standout, climbing on signs that the social media giant's CEO has ...
Stocks rose Thursday, rebounding after earlier losses as Wall Street weighed Federal Reserve Chair Jerome Powell's comments on the central bank continuing to fight inflation. The Dow Jones Industrials faded 37.31 points to open Thursday at 31,543.97 The S&P 500 dipped 3.89 point...
Stocks were flat Thursday as Wall Street weighed Federal Reserve Chair Jerome Powell's comments on the central bank continuing to fight inflation. The Dow Jones Industrials faded 37.31 points to open Thursday at 31,543.97 The S&P 500 dipped 3.89 points to 3,975.39 The NASDAQ...
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis PR Newswire Nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and ...
Regeneron ( NASDAQ: REGN ) announced Thursday that its blockbuster eye medication Eylea reached the primary endpoints in two pivotal trials designed to investigate a less frequent dosing regimen in patients with diabetic macular edema (DME) and wet age-related macular degenerati...
Regeneron ( NASDAQ: REGN ) announced Thursday that its blockbuster eye medication Eylea reached the primary endpoints in two pivotal trials designed to investigate a less frequent dosing regimen in patients with diabetic macular edema (DME) and wet age-related macular degenera...
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals PR Newswire 91% and 89% of diabetic macular edema (DME) patients were rapidly initiated and maintaine...
Summary Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020. The company has a dividend yield of 5.08%, but dividend payouts are at risk from 2026....
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma PR Newswire Results from the longest global Phase 3 open-label extension trial in thi...
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers PR Newswire First-in-class Phase 1 data for two investigational bispecifics in advanced ovarian...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...